We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ultragenyx (RARE) Reports FDA Removal of Clinical Hold on Study
Read MoreHide Full Article
Ultragenyx Pharmaceutical Inc. (RARE - Free Report) , along with partner GeneTx Biotherapeutics LLC, a privately-held biotechnology company, announced that the FDA has removed the clinical hold from their phase I/II study evaluating GTX-102 for the treatment of Angelman Syndrome, a rare neurogenetic disorder.
The companies can now begin dosing naïve patients in the above-mentioned study for treating pediatric patients with Angelman syndrome. The open-label, multiple-dose study will evaluate the safety, tolerability, and plasma and cerebrospinal fluid concentrations of GTX-102 in the given patient population.
Per the company, under the amended study protocol in the United States, eight patients aged between four to less than eight years who have not received previous treatment with GTX-102 will be enrolled in the study into two groups – an active group and an age-matched comparator group.
Patients in the active group will receive four monthly doses of GTX-102 (2 mg), while patients in the comparator group will have limited assessments at baseline and day 128.
Shares of Ultragenyx declined 35.9% so far this year compared with the industry’s decrease of 1.3%.
Image Source: Zacks Investment Research
We remind investors that last October, Ultragenyx announced interim data from the phase I/II study on GTX-102 for treating Angelman syndrome. Data from the same showed that all the patients who were treated with GTX-102 had experienced substantial improvements in at least two disease domains, including communication, behavior, sleep, gross motor function and fine motor function, as measured by the Clinical Global Impression of Improvement Scale for Angelman Syndrome at day 128.
However, all patients experienced a serious adverse event of lower extremity weakness related to local inflammation following treatment with the highest doses of GTX-102. Back then, the companies decided to cease enrollment and dosing in the study.
Earlier this year, Health Canada cleared a protocol amendment and the Medicines and Healthcare Products Regulatory Agency in the United Kingdom approved a Clinical Trial Application to initiate the phase I/II study on GTX-102 in the two countries, respectively. Early clinical data from the same is expected before the end of 2021.
Spero Therapeutics’ loss per share estimates have narrowed 8.2% for 2021 and 10.6% for 2022 over the past 60 days.The stock has inched up 0.4% year to date.
Corvus Pharmaceuticals’ loss per share estimates have narrowed 13.9% for 2021 and 7.2% for 2022, over the past 60 days. The stock has skyrocketed 115.5% year to date.
Vertex’s earnings estimates have been revised 10.2% upward for 2021 and 7.3% upward for 2022 over the past 60 days.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ultragenyx (RARE) Reports FDA Removal of Clinical Hold on Study
Ultragenyx Pharmaceutical Inc. (RARE - Free Report) , along with partner GeneTx Biotherapeutics LLC, a privately-held biotechnology company, announced that the FDA has removed the clinical hold from their phase I/II study evaluating GTX-102 for the treatment of Angelman Syndrome, a rare neurogenetic disorder.
The companies can now begin dosing naïve patients in the above-mentioned study for treating pediatric patients with Angelman syndrome. The open-label, multiple-dose study will evaluate the safety, tolerability, and plasma and cerebrospinal fluid concentrations of GTX-102 in the given patient population.
Per the company, under the amended study protocol in the United States, eight patients aged between four to less than eight years who have not received previous treatment with GTX-102 will be enrolled in the study into two groups – an active group and an age-matched comparator group.
Patients in the active group will receive four monthly doses of GTX-102 (2 mg), while patients in the comparator group will have limited assessments at baseline and day 128.
Shares of Ultragenyx declined 35.9% so far this year compared with the industry’s decrease of 1.3%.
We remind investors that last October, Ultragenyx announced interim data from the phase I/II study on GTX-102 for treating Angelman syndrome. Data from the same showed that all the patients who were treated with GTX-102 had experienced substantial improvements in at least two disease domains, including communication, behavior, sleep, gross motor function and fine motor function, as measured by the Clinical Global Impression of Improvement Scale for Angelman Syndrome at day 128.
However, all patients experienced a serious adverse event of lower extremity weakness related to local inflammation following treatment with the highest doses of GTX-102. Back then, the companies decided to cease enrollment and dosing in the study.
Earlier this year, Health Canada cleared a protocol amendment and the Medicines and Healthcare Products Regulatory Agency in the United Kingdom approved a Clinical Trial Application to initiate the phase I/II study on GTX-102 in the two countries, respectively. Early clinical data from the same is expected before the end of 2021.
Zacks Rank & Stocks to Consider
Ultragenyx currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Spero Therapeutics, Inc. (SPRO - Free Report) , Corvus Pharmaceuticals, Inc. (CRVS - Free Report) and Vertex Pharmaceuticals Incorporated (VRTX - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Spero Therapeutics’ loss per share estimates have narrowed 8.2% for 2021 and 10.6% for 2022 over the past 60 days.The stock has inched up 0.4% year to date.
Corvus Pharmaceuticals’ loss per share estimates have narrowed 13.9% for 2021 and 7.2% for 2022, over the past 60 days. The stock has skyrocketed 115.5% year to date.
Vertex’s earnings estimates have been revised 10.2% upward for 2021 and 7.3% upward for 2022 over the past 60 days.